List of works - Kevin D Read

A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors

scientific article published on 12 September 2018

A novel multiple-stage antimalarial agent that inhibits protein synthesis

scientific article (publication date: 18 June 2015)

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania

scientific article

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

scientific article published on 27 February 2017

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

scientific article published on 05 June 2017

Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

scientific article published on 01 November 2018

Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase

scientific article

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani

scientific article published on 2 October 2017

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

scientific article published on 25 May 2016

Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis

scientific article

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

scientific article published in Nature

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

scientific article

Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

scientific article published on 05 March 2020

Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei

scientific article published on 29 September 2015

Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library

scientific article published on 18 September 2015

Discovery of a Novel Class of Orally Active Trypanocidal N -Myristoyltransferase Inhibitors

scientific article

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

scientific article published on 10 September 2016

Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis

scientific article

Identification and optimisation of a series of 8-hydroxy naphthyridines with potent in vitro antileishmanial activity: Initial SAR and assessment of in vivo activity

scientific article published on 14 July 2020

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

scientific article published on 20 December 2018

Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB

scientific article published on 26 July 2018

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis

scientific article

Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis

scientific article

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

scientific article published on 20 March 2019

N-myristoyltransferase inhibitors as new leads to treat sleeping sickness

scientific article

Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future

scientific article published on 10 September 2018

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani

scholarly article by Victoriano Corpas-Lopez et al published 12 November 2018 in ACS Infectious Diseases

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

scientific article published on 08 April 2019

Setting Our Sights on Infectious Diseases

scientific article published on 06 December 2019

Targeting N-myristoylation for therapy of B-cell lymphomas

scientific article published on 22 October 2020

The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis

scientific article

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis

scientific article

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

scientific article published on 24 May 2016

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

scientific article published on 17 June 2016

Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs

scientific article published on 03 November 2020

List of works by Kevin D Read

A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors

A novel multiple-stage antimalarial agent that inhibits protein synthesis

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei

Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library

Discovery of a Novel Class of Orally Active Trypanocidal N -Myristoyltransferase Inhibitors

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis

Identification and optimisation of a series of 8-hydroxy naphthyridines with potent in vitro antileishmanial activity: Initial SAR and assessment of in vivo activity

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis

Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

N-myristoyltransferase inhibitors as new leads to treat sleeping sickness

Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Setting Our Sights on Infectious Diseases

Targeting N-myristoylation for therapy of B-cell lymphomas

The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs